NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Advaxis Inc. (OTCBB: ADXS, http://www.advaxis.com), a developmental biotechnology company, presented landmark clinical trial results of its flagship drug candidate, Lovaxin C, at the American Associate for Cancer Research (“AACR”) this past Sunday, April 13th, in San Diego, CA.
